Pre-RAI monocyte-to-lymphocyte ratio predicts recurrence risk in intermediate-risk differentiated thyroid cancer, suggesting improved follow-up strategies.
Pre-RAI MLR may serve as a simple marker to refine recurrence risk stratification and personalize follow-up in intermediate-risk DTC.
No takes yet. Share an insight, caveat, or question.
Piticchio et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: